Impact of Omega-3 Fatty Acid Supplementation on Cardiovascular Health
DOI:
https://doi.org/10.47672/ajfsn.1782Keywords:
Omega-3, Fatty Acid, Supplementation, Cardiovascular HealthAbstract
Purpose: The aim of the study was to investigate the impact of omega-3 fatty acid supplementation on cardiovascular health.
Methodology: This study adopted a desk methodology. A desk study research design is commonly known as secondary data collection. This is basically collecting data from existing resources preferably because of its low cost advantage as compared to a field research. Our current study looked into already published studies and reports as the data was easily accessed through online journals and libraries.
Findings: Omega-3 fatty acid supplementation has a positive impact on cardiovascular health by reducing the risk of heart attacks and strokes, lowering blood pressure, improving lipid profiles, and providing anti-inflammatory and anti-arrhythmic effects. It is particularly beneficial for individuals with heart conditions. However, dosages matter, and individual health factors should be considered before starting supplementation.
Implications to Theory, Practice and Policy: Inflammation theory, lipid theory and platelet aggregation theory may be use to anchor future studies on the impact of omega-3 fatty acid supplementation on cardiovascular health. Develop and update clinical guidelines that provide clear recommendations for healthcare practitioners regarding the appropriate use of Omega-3 fatty acid supplementation in various patient populations. Regulation and Quality Control: Advocate for stringent regulation and quality control measures within the supplement industry.
Downloads
References
Adeloye, D., Basquill, C., Aderemi, A. V., & Thompson, J. Y. (2020). Estimating the prevalence, hospitalisation and mortality from hypertension in Nigeria: a systematic review and meta-analysis. Journal of Hypertension, 38(3), 307-316. DOI: 10.1097/HJH.0000000000002296
Ataguba, J. E. O., Akazili, J., McIntyre, D., & Day, C. (2020). Paying for and receiving benefits from health services in South Africa: is the health system equitable? The Lancet Global Health, 8(4), e589-e602. DOI: 10.1016/S2214-109X(19)30554-0
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., ... & Virani, S. S. (2019). Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation, 139(10), e56-e528. DOI: 10.1161/CIR.0000000000000659
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., ... & Ballantyne, C. M. (2019). Cardiovascular risk reduction with Icosapent Ethyl for hypertriglyceridemia. New England Journal of Medicine, 380(1), 11-22.
Bowman, L., Mafham, M., Wallendszus, K., Stevens, W., Buck, G., Barton, J., ... & Parish, S. (2021). Effects of n−3 fatty acid supplements in diabetes mellitus. New England Journal of Medicine, 385(19), 1727-1739.
Cadd, R., Hancox, J., & Green, R. (2019). Trends in cardiovascular disease over a decade in Australia: A report from the Australian Bureau of Statistics. Medical Journal of Australia, 211(8), 354-355. DOI: 10.5694/mja2.50313
Cho, E. J., Rhee, E. J., Park, S. E., & Kwon, H. (2019). Trends in the prevalence and management of cardiovascular risk factors among adults in South Korea. Journal of the American College of Cardiology, 73(9), 2606-2608. DOI: 10.1016/j.jacc.2019.02.058
Gathecha, G., Otieno, L., Ondicho, D., Amwayi, S., Othoo, G., Kiptui, D., ... & Bucher, S. (2020). Prevalence, awareness, treatment and control of hypertension and their determinants: results from a national survey in Kenya. BMC Public Health, 20(1), 1-11. DOI: 10.1186/s12889-020-09292-y
GBD 2019 Collaborators. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 396(10258), 1204-1222. DOI: 10.1016/S0140-6736(20)30925-9
Harris, W. S., Mozaffarian, D., Lefevre, M., Toner, C. D., Colombo, J., & Cunnane, S. C. (2008). Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. Journal of Nutrition, 138(10), 2050S-2059S.
Hernández-Ávila, M., Rivera-Dommarco, J., Shamah-Levy, T., Cuevas-Nasu, L., Gaona-Pineda, E. B., Gómez-Acosta, L. M., ... & Villalpando-Hernández, S. (2021). Encuesta Nacional de Salud y Nutrición de Medio Camino 2016: Informe final de resultados. Instituto Nacional de Salud Pública. DOI: 10.13140/RG.2.2.14763.49444
Keys, A., Taylor, H. L., Blackburn, H., Brozek, J., Anderson, J. T., & Simonson, E. (1953). Coronary heart disease among Minnesota business and professional men followed fifteen years. Circulation, 8(3), 381-389.
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010). n-3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine, 363(21), 2015-2026.
Li, Y., Yang, L., Wang, L., Zhang, M., Huang, Z., Deng, Q., ... & Wang, L. (2019). Burden of hypertension in China: a nationally representative survey of 174,621 adults. The Lancet, 394(10196), 652-662. DOI: 10.1016/S0140-6736(19)31705-3
Maki, K. C., Palacios, O. M., Bell, M., Toth, P. P., Vuppalanchi, R., Stolzenberg-Solomon, R., ... & Bays, H. E. (2019). Effects of prescription omega-3 acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. Journal of Clinical Lipidology, 13(4), 568-578.
Malachias, M. V. B., Souza, W. K. S. B., Plavnik, F. L., & Rodrigues, C. I. S. (2020). 7th Brazilian Guideline of Arterial Hypertension: Chapter 2 - Diagnosis and Classification. Brazilian Journal of Medical and Biological Research, 53(11), e10385. DOI: 10.1590/1414-431X202010385
Marik, P. E., & Varon, J. (2009). Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clinical Cardiology, 32(7), 365-372.
Mozaffarian, D., & Wu, J. H. (2011). Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. Journal of the American College of Cardiology, 58(20), 2047-2067.
Poulter, N. R., Prabhakaran, D., Caulfield, M. J. (2020). Hypertension. The Lancet, 395(10217), 938-951.
Ridker, P. M. (1997). Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagulation & Fibrinolysis, 8(Suppl 1), S9-S12.
Sathish, T., Kapoor, N., Cao, Y., Tandon, N., & Poston, L. (2019). Prevalence of hypertension and associated risk factors in a South Indian population: A cross-sectional study. PLOS ONE, 14(1), e0214338. DOI: 10.1371/journal.pone.0214338
Shalnova, S., Cook, S., Balanova, Y., Breda, J., & Azaïs-Braesco, V. (2018). Trends in cardiovascular disease mortality in Russia and the United States: understanding the divergence. Circulation, 137(13), 1291-1300. DOI: 10.1161/CIRCULATIONAHA.117.032646
Vane, J. R., & Änggård, E. E. (1970). Prostacyclin (PGX): A vascular mediator that inhibits platelet aggregation. Nature, 246(5431), 215-217.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Benard Muiti
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
